Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
OCUL Catalyst Timeline
Dated clinical, regulatory and corporate events for Ocular Therapeutix, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ocular Therapeutix, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How OCUL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-12 | OTX-TKI (intravitreal axitinib hydrogel / Axpaxli) | Phase 3 data presentation | Phase 3 |
Drug Pipeline Intelligence
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| DEXTENZA |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OTX-TKI Small MoleculesNCT06495918 | Neovascular Age-related Macular Degeneration | Phase 3 | ACTIVE NOT_RECRUITING | 2,069 | Jan 8, 2027 | ||||||
| OTX-TKI Small MoleculesNCT07235085 | Non-Proliferative Diabetic Retinopathy | Phase 3 | RECRUITING | 930 | Mar 1, 2027 | ||||||
| OTX-TIC low dose Travoprost Intracameral Small MoleculesCompletedNCT05335122 | Open Angle Glaucoma | Phase 2 | COMPLETED | 83 | Jan 24, 2025 | ||||||
| OTX-TIC Medical DevicesCompletedNCT04360174 | Ocular Hypertension | Phase 1 | COMPLETED | 19 | May 24, 2021 | ||||||
| OTX-DED Small MoleculesCompletedNCT05814757 | Dry Eye Syndromes | Phase 2 | COMPLETED | 100 | May 22, 2024 | ||||||
| OTX-DED Small MoleculesCompletedNCT04747977 | Dry Eye | Phase 2 | COMPLETED | 172 | Sep 22, 2021 | ||||||
| OTX-CSI Small MoleculesCompletedNCT04362670 | Dry Eye Disease | Phase 1/2 | COMPLETED | 153 | Aug 11, 2021 | ||||||
| Dextenza Insert Small MoleculesNot countedNCT04539548 | Cataract | Phase 3 | COMPLETED | 65 | Dec 21, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every OCUL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| AXPAXLI | wet AMD | Phase 3 | 2026-04-13 | median time of 39 weeks and 46 weeks to≥30 and≥75 uM increases from Week 8; median time to ≥30 uM Central Subfield Thickness (CSFT) increase from Week 8 was 39 weeks in the AXPAXLI group and 16 weeks in the aflibercept (2 mg) group, a 23-week difference; estimated hazard ratio of 0.7Read More | Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMDRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Saroj NamrataOfficer (Chief Business Officer) | Sell | -35,370 220,522 held | $6.55 | 11/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in OCUL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 2.7 % (-3.6 %) | 168.28 M | 21.94 M | 11.45% ( 2.25 M) |
Ownership Trends
OCUL Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How OCUL ranks across every disease it competes in
OCUL News
Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights
Ocular Therapeutix reported its Q3 2026 financial results, highlighting the NDA submission for AXPAXLI for wet AMD, expected in 4Q 2026. The company noted positive outcomes from the SOL-1 trial, with 70% of subjects remaining dry at Week 36. However, it also reported a net loss of $(94.8) million and a decrease in revenue compared to the previous year.
Read more →Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix announced the grant of inducement equity awards to eight new non-executive employees. The awards include stock options for 35,775 shares and restricted stock units for 11,725 shares, effective November 2, 2026. These grants are part of the company's strategy to attract talent under its 2019 Inducement Stock Incentive Plan.
Read more →Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026
Ocular Therapeutix will host a conference call on November 9, 2026, to discuss its third quarter financial results. The company is advancing its investigational product AXPAXLI in Phase 3 trials for wet AMD and diabetic retinal disease. Additionally, it has a pipeline that includes the FDA-approved DEXTENZA and the OTX-TIC candidate.
Read more →Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences
Ocular Therapeutix announced its participation in several investor and scientific conferences in November 2026. Key events include a fireside chat at the UBS Global Biopharma Conference and presentations at The Empire Forum and OSN New York. The discussions will focus on advancements in retinal disease treatments.
Read more →Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences
Ocular Therapeutix, Inc. announced its participation in several scientific and investor conferences in October 2026. Highlights include presentations on their investigational product AXPAXLI for retinal diseases at major events like the Chardan Healthcare Conference and the American Academy of Ophthalmology. The company aims to redefine the retina experience through innovative therapies.
Read more →Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
Ocular Therapeutix announced a successful Pre-NDA Meeting with the FDA for AXPAXLI, an investigational treatment for wet AMD. The company is on track to submit the NDA in Q4 2026, based on robust efficacy and safety data from clinical trials. AXPAXLI could become the first TKI approved for wet AMD, with commercial preparations underway for a potential 2027 launch.
Read more →Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
Ocular Therapeutix, Inc. will participate in several investor and scientific conferences in September and October 2026. Key events include the Wells Fargo Healthcare Conference and the Retina Society Annual Meeting, where they will present findings on their investigational product AXPAXLI for retinal diseases. The company aims to highlight advancements in treatment options for conditions like wet AMD.
Read more →Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
Ocular Therapeutix reported its Q2 2026 financial results, highlighting progress on the NDA submission for AXPAXLI for wet AMD, expected in Q4 2026. The company confirmed FDA alignment and presented data suggesting a significant reduction in treatment burden with AXPAXLI. Despite a net loss of $(78.8) million, Ocular maintains a strong cash position to support its operations into 2028.
Read more →Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
Ocular Therapeutix, Inc. announced its participation in several scientific and investor conferences in July 2026. Key presentations will focus on advancements in retinal therapies, including results from the Phase 3 SOL-1 trial for AXPAXLI. The company aims to redefine the retina experience through innovative treatments and ongoing clinical trials.
Read more →Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
Ocular Therapeutix announced its plans to submit a New Drug Application (NDA) for AXPAXLI in wet AMD by Q4 2026, based on positive SOL-1 trial data. The company will conduct an interim safety analysis for the SOL-R trial to meet FDA requirements. AXPAXLI aims to differentiate itself from existing treatments like aflibercept, with a new secondary endpoint added to the SOL-R trial. The company is also streamlining its diabetic retinopathy program to focus on the HELIOS-3 trial.
Read more →Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
Ocular Therapeutix, Inc. announced its participation in the Clinical Trials at the Summit 2026, held on June 12-13 in Las Vegas, Nevada. The event includes presentations on the company's investigational product AXPAXLI, aimed at treating neovascular AMD and diabetic retinal diseases. Significant discussions will focus on the safety and efficacy outcomes of OTX-TKI. This participation emphasizes Ocular's dedication to innovation and leadership in retinal disease therapies.
Read more →Ocular Therapeutix™ to Host Investor Day on June 17, 2026
Ocular Therapeutix will host an Investor Day on June 17, 2026, in New York City, featuring presentations from company leadership and retinal disease experts. The event will cover the NDA submission plan for AXPAXLI in wet AMD, updates on ongoing trials, and commercialization strategies. A live Q&A session and networking reception will conclude the event.
Read more →